Background Clinician-rated measures of functioning are often used as primary endpoints in clinical trials and other behavioral research in Huntington disease. As study costs for clinician-rated assessments are not always feasible, there is a question of whether patient self-report of commonly used clinician-rated measures may serve as acceptable alternatives in low risk behavioral trials. Aim The purpose of this paper was to determine the level of agreement between self-report and clinician-ratings of commonly used functional assessment measures in Huntington disease. Design 486 participants with premanifest or manifest Huntington disease were examined. Total Functional Capacity, Functional Assessment, and Independence Scale assessments from the Unified Huntington Disease Rating scale were completed by clinicians; a self-report version was also completed by individuals with Huntington disease. Cronbach's α was used to examine internal consistency, one-way analysis of variance was used to examine group differences, and paired t tests, kappa agreement coefficients, and intra-class correlations were calculated to determine agreement between raters. Results Internal consistency for self-reported ratings of functional capacity and ability were good. There were significant differences between those with premanifest, early-, and late-stage disease; those with later-stage disease reported less ability and independence than the other clinical groups. Although self-report ratings were not a perfect match with associated clinician-rated measures, differences were small. Cutoffs for achieving specified levels of agreement are provided. Conclusions Depending on the acceptable margin of error in a study, self-reported administration of these functional assessments may be appropriate when clinician-related assessments are not feasible.
Introduction
Huntington disease (HD) is an autosomal dominant inherited, progressive neurodegenerative disorder that causes profound cognitive, behavioral, and motor decline [1, 2] . The disease often manifests near age 40 and leads to death in 15-20 years [1, 3, 4] . Patients lose function in many areas, including occupational, social, financial, and activities of daily living [5] [6] [7] . Slowing functional loss is a major unmet need, and a prime goal of HD clinical trials [8, 9] . These trials require functional rating scales that, in some cases, may act as a primary endpoint [5, 10] .
The Unified Huntington's Disease Rating Scale (UHDRS) is the most widely used assessment in clinical HD research [11] . The UHDRS includes clinician-rated assessments of functioning, motor symptoms, and cognition. With regard to the UHDRS functional assessments it includes: the Total Functional Capacity (TFC), the Functional Assessment (FA) Scale, and the Independence Scale [11, 12] . The TFC in particular is a frequently used as a primary outcome measure, e.g., [13] [14] [15] . The entire UHDRS, including these scales, was designed and validated as a clinician-rated instrument [11] . The clinician completes the scales after focused interviews with the affect individual and/or a close informant.
Some behavioral and observation research trials in HD would substantially benefit if these scales could be accurately completed by patient self-report. Patients could then complete their own functional ratings electronically from home, for at least some time points, reducing the participant burden for studies that require frequent administrations of functional scales [16] . This could potentially decrease study costs and enhance recruitment and retention [16, 17] . Furthermore, patient-reported outcome measures, particularly as they pertain to health-related quality of life (HRQOL; the effect of a disease on one's physical, cognitive, emotional, or social well-being [18, 19] ) are becoming increasingly important as measures of efficacy for new treatments [20, 21] .
On the other hand, relying on patient self-report has potential disadvantages. One key question is whether selfratings would be similar to (and therefore a reasonable substitute for) a trained clinician's ratings using these functional rating scales. Cognitive dysfunction occurs even in premanifest HD (before motor symptoms manifest) [5, [22] [23] [24] [25] , and patient-reported and caregiver-reported functional ratings may diverge in the early stages of disease, possibly related to subtle loss of awareness on the patient's part [26] [27] [28] [29] [30] [31] . These discrepancies might increase in late-stage HD, when dementia could interfere with a subject's insight and item comprehension, or lead to perseverative responses. Another potential source of error is misunderstanding of a question's intent. Most notably, many items in the UHDRS are intended to gauge the capacity to perform function X or Y, regardless of whether the subject actually performs X or Y with any regularity. This potential source of confusion could be mitigated with a trained clinician guiding the rating.
The broader literature comparing self-report to clinical interview data is extremely variable. For example, while there is often consensus between self-reported and clinician interview for clinical diagnoses [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] , consensus reporting between the patient and clinician for specific symptoms and overall functioning can be highly variable [42] [43] [44] [45] [46] . Furthermore, the accuracy of retrospective selfreported symptoms may suffer from recall bias or memory decay [47, 48] , and may be subject to exaggeration, especially in cases where litigation or compensation is involved [38] [39] [40] [41] . Several different factors may account for this variability including the objectivity/subjectivity of the symptom that is the subject of the report, social desirability, time length for recall, the age and education of the informant, and the level of self-awareness of the rater. More work is needed to understand how patient self-report in HD relates to clinician-ratings.
The primary aim of this analysis was to compare clinician-reported and patient-reported ratings of UHDRS functional measures. We hypothesized that for premanifest and early-HD subjects, self-report would correlate well with clinician-report, but that increased discrepancy may occur in later-stage HD. In addition, we examined the reliability of individual items (and groups) across different raters and compared the internal consistency of clinician and self-reported measures to determine if one measure was more stable than the other. We hypothesized that clinician-ratings would have greater stability than self-report measures. Finally, we examined the ability for both the clinician-ratings and self-report ratings to differentiate between those with premanifest versus manifest disease (i.e., known groups validity). Since those with manifest disease have greater functional deficits than those with premanifest disease [49] , this would provide evidence of validity.
Methods

Participants
Participants with either premanifest (gene-positive status for the HD CAG expansion and no clinical diagnosis), or manifest HD were invited to participate in a study about HRQOL (characterization details provided below). This report focuses on a subset of participants that were examined as part of a larger study; detailed data about the full sample are reported elsewhere [50] . Briefly, participants must have been ≥ 18 years of age, able to read and understand English, and able to provide informed consent. This convenience sample included recruitment efforts through local HD treatment centers (at the University of Michigan, University of Iowa, University of California-Los Angeles, Indiana University, Johns Hopkins University, Rutgers University, Struthers Parkinson's Center, and Washington University in St. Louis), the HD Roster, existing online medical record data capture systems [51] , and community outreach. In addition, a portion of this sample was recruited in conjunction with the Predict-HD research study [52] . All study activities were conducted with the approval of local Institutional Review Boards and have, therefore, been performed in accordance with the ethical standards in the 1964 Declaration of Helsinki. Consent from participants was also obtained before subject participation began.
Characterization of Huntington disease (HD)
The Total Motor Scale and the Total Functional Capacity score from the Unified Huntington's Disease Rating Scale (UHDRS) [11] were used to classify HD participants in this study. The 15-item clinician administered TMS evaluates multiple aspects of motor functioning (scores range from 0 to 124 with higher scores indicating more motor difficulties). The final item of this scale requires the clinician to indicate a confidence rating for whether or not the participant has unequivocal signs of HD (the rating scale ranges from 0 = no abnormalities to 4 = ≥ 99% confidence). To be classified as having premanifest HD, participants were required to have a positive gene test for the HD CAG expansion (CAG > 35) and a clinician confidence rating of ≤ 4 on the last item of the TMS. To be classified as manifest HD, participants were required to have a clinician-based rating of 4 on the last item of the TMS. Staging for manifest participants was determined based on TFC scores (which includes five multiple-choice clinician-rated items addressing impairment or assistance required in occupation, finances, domestic chores, ADLs, and level of care). Scores range from 0 to 13 with higher scores indicating better functioning; early-HD (stages I-II) had TFC scores between 7 and 13 and late-HD (stages III-IV) had TFC scores between 0 and 6.
Measures
Demographics
Demographic information was collected using an online data capture system (Assessment Center SM ). Demographic data included age, gender, marital status, race, and ethnicity.
Medical record confirmation
Medical record data were retrieved to confirm HD diagnosis, date of HD diagnosis, and gene test results (including CAG repeat length). For manifest participants, the date of HD diagnosis was used to determine how many years had passed from diagnosis to the time of their study visit. For premanifest participants, the CAG repeat length and age at the time of their study visit were used to calculate their CAP score [53] , which categorizes participants as either Low, Intermediate, and High risk of developing motor symptoms within the next 5 years.
The Unified Huntington's Disease Rating Scale (UHDRS) [11]
The UHDRS is a standardized rating scale that assesses mobility, cognition, functionality, and independence [11] . We examined three measures: Total Functional Capacity (TFC), the Functional Assessment (FA) Scale, and the Independence Scale. Two different administrations of these assessments were completed; the first was clinicianrated, and the second was patient self-reported (see Online Appendix for self-report versions of these assessments). The TFC includes five multiple-choice questions addressing impairment or assistance required in occupation, finances, domestic chores, ADLs, and level of care. Both clinicianrated and self-report TFC scores range from 0 to 13 with higher scores indicating better functioning [11] . The Functional Assessment Scale includes 25 yes/no questions pertaining to a participant's ability to perform common tasks related to occupation, finances, activities of daily living (ADL), domestic chores, and level of care. Scores range from 0 to 25 for the clinician-rated and self-report version of this measure, with higher scores indicating higher functioning [11] . The clinician-rated Independence Scale is rated from 1 to 100 in intervals of five, with higher scores indicating higher functioning and lower scores indicating worse functioning [11] . The self-report Independence scale differs slightly, in that participants rate themselves on a scale of 0-10, without an option to select increments of 0.5. For the purposes of this analysis, the clinician-rated Independence scale was transformed by dividing the clinician score (ranging from 0 to 100) by 10 to match the scale of the self-report measure (0-10).
Statistical analysis
Statistical analyses were performed with SAS 9.4 and SPSS Version 22.0 [54, 55] . Descriptive statistics were analyzed separately for both the clinician rating and self-reported scores.
Reliability
Cronbach's α coefficients were calculated to determine internal consistency of the UHDRS TFC and Functional Assessment for the clinician-rated and participant self-report. A critical cutoff of 0.70 was considered minimal acceptable reliability [56] . We used a dependent alpha (Feldt) t test [57] to compare clinician and self-report measures of the same test. The Independence Scale is comprised of a single item; therefore, internal consistency cannot be calculated.
Known groups validity
Known groups validity was assessed using a one-way ANOVA to determine whether the clinician and selfreported FA and Independence Scales could differentiate among the three HD groups. We hypothesized that premanifest participants would report higher levels of independence and functioning than the early-stage HD group, and that the early-stage HD group should report more independence and better functioning than the late-stage HD group [49] . Bonferroni (Dunn) t tests were used to examine mean differences among the three groups [58] . Known groups validity was not assessed for TFC scores, since TFC scores are required to determine the HD staging groups.
Measurement agreement between clinician-rated and self-report scores
The clinician-rated and self-report scores were compared using a paired t test to determine the statistical significance of the mean difference in total TFC, FA, and Independence Scale scores. Next, individual TFC and FA items were compared between the clinician-rated and participant self-report rating using Cohen's kappa coefficient [59] . A kappa score between 0.81 and 1 was considered excellent agreement, 0.61-0.80 was considered substantial (very good) agreement, 0.41-0.60 was moderate agreement, 0.21-0.40 was deemed fair agreement, and lower than 0.20 indicated no agreement [59, 60] . A kappa coefficient for the Independence Scale could not be calculated because the clinician and the participant-rated scales differed (i.e., the clinician was allowed to choose intervals of 5). Intra-class correlation coefficients (ICCs) were calculated to analyze the group level reliability of the clinician-rated items and the selfreported items. Overall agreement was measured by finding the percent of participants whose self-reported scores and clinician-rated assessment scores were an exact match. Then, agreement between clinician-rated and self-reported Functional Assessment scores and TFC scores was examined at ascending discrepancy allowances to assess how much discrepancy would allow for different levels (75, 90, 95, and 100%) of agreement.
Results
Descriptive data
We examined 486 individuals with either premanifest (n = 195) or manifest HD (early stage n = 190 or late stage n = 101). Groups did not differ on gender (Χ 2 2 = 4.0, p = 0.1341). As expected, age significantly differed across groups (F[2,483] = 45.3, p < 0.0001); the average age of the premanifest group (M = 42.9; SD = 12.2) was 9 years younger than the early group (M = 52.0; SD = 12.3) and 13 years younger than the late-stage group (M = 55.5; SD = 11.6). This is understandable given the progressive nature of the disease and the usual age of onset. Race (Fisher's exact p = 0.0053) and ethnicity (Fisher's exact p = 0.0002) also differed across groups; the late-stage group had a higher proportion of African Americans than the other two groups, the late-stage group included a higher proportion of non-Hispanic participants than the other two groups and the premanifest group had a larger proportion of individuals whose ethnicity was not provided relative to the manifest groups. A description of the sample can be found in Table 1 . The average score for the clinician rating of TFC was 9.54 (SD = 3.68). This 
Reliability
Internal consistency data are provided in Table 2 . Internal consistency for the clinician-rated TFC was good (Cronbach's α = 0.89) and FA was excellent (Cronbach's α = 0.95). Similarly, internal consistency was good for the self-reported TFC (Cronbach's α = 0.86) and excellent for the FA (Cronbach's α = 0.95). The internal consistency for the self-reported TFC (Cronbach's α = 0.86) was significantly lower than the clinician-rated TFC (t[468] = 4.75; p < 0.0001). Similarly, the self-report administration of the FA (Cronbach's α = 0.94) was also significantly lower than the clinician assessment (t[301] = 2.16; p = 0.03), though numerically and clinically this difference is small.
Known groups validity
For the FA and the Independence Scale, both the clinicianrated measure and self-report measure were differentiated among the HD groups (Table 3 ). All findings were in the hypothesized direction (i.e., premanifest participants reported higher levels of independence and functioning than the early-stage HD group, and the early-stage HD group reported more independence and functioning than the late-stage HD group).
Measurement agreement between clinician-rated and self-report scores
The clinician-rated TFC significantly differed from selfreport TFC (t[469] = 6.10; p < 0.0001; Table 2 ). These significant differences were seen for both the premanifest (t[189] = 4.31; p < 0.0001) and early (t[180] = 5.87; p < 0.0001) groups; in both cases clinicians rated participants as higher functioning than the participants themselves did. However, TFC scores did not significantly differ in the late-stage group (t[98] = 0; p = 1). At the individual level, there was 21.5% agreement between clinician-rated and selfreported scores. To achieve 75, 90, 95, and 100% agreement, clinician-rated and participant self-report scores had to be within 2, 4, 5, and 7 points of each other, respectively (Table 4) . Although the kappa was 0.14 (indicating no interrater reliability) and agreement for the individual items was minimal to weak (kappa scores ranged from 0.17 to 0.58), the intra-class correlations for the total score was good (ICC = 0.88; 95% CI 0.85, 0.90; see Table 5 ).
For the FA scale, clinician-ratings did not differ from the self-report scores for the overall sample (t[303] = 1.01; p = 0.3141; < 0.0001), early-HD participants were older than premanifest participants and late-HD was older than early-HD; education (# of years), premanifest participants had more years of education than the other two groups (F[2,481] = 13.1; p < 0.0001); race (White, African American, More than One Race, American Indian/Alaskan Native, Other, Not Provided), late-HD had more African Americans than the other two groups, the premanifest group had more mixed race participants than the other groups (Fisher's exact p = 0.0053); ethnicity (not Hispanic/Latino, Hispanic/Latino, not provided), more premanifest participant did not provide an ethnicity, late-HD had more non-Hispanic/Latinos than the other two groups (Fisher's exact p = 0.0002); marital status (single, married, separated/ divorced, widowed, living with partner), Premanifest participants were less likely to be separated/divorced or widowed than the other two groups (Χ 8 2 = 21.9, p = 0.0051); and time since diagnosis (in years, manifest only), the late-HD group had approximately 3 more years since diagnosis than the early-HD group (t[135.5] = − 4.7; p < 0.0001) **Disease burden was measured using CAP scores [53] total score, there was 29.9% exact agreement between the clinician and subjects, and a 75% agreement within a 2-point window. To achieve 75, 90, 95, and 100% agreement, FA scores needed to be within 2, 5, 7, and 13 points, respectively (Table 4) . Although the kappa was 0.23 (indicating minimal inter-rater agreement), the intra-class correlation coefficient was excellent for the total score (ICC = 0.90; 95% CI 0.92, 0.95; Table 5 ). With regard to individual items, kappa scores ranging from 0.30 to 0.85, indicating minimal to strong rater agreement (Table 5 ).
For the Independence Scale, clinician-rated significantly differed from self-report scores (t[481] = 6.24; p < 0.0001; Table 3 ). There was 52% agreement between the clinician-rated and self-report Independence Scale scores. To achieve 75, 90, 95, and 100% agreement, clinician-rated and self-report scores need to be within 1 point, 2, points, 2 points, and 6 points, respectively (Table 4) . Intra-class correlations for the Independence Scale were acceptable (ICC = 0.88; 95% CI 0.85, 0.90; Table 5 ). Table 4 Total score differences required to achieve specified levels of agreement 75% 90% 95% 100%
Total Functional Capacity 2 points 4 points 5 points 7 points Functional Assessment 2 points 5 points 7 points 13 points Independence Scale 1 point 2 points 2 points 6 points
Discussion
The purpose of this study was to examine the accuracy of self-report reported functioning in individuals with HD relative to associated clinician-ratings of the same construct. While self-report ratings and clinician-ratings were not a perfect match, self-ratings provided a reliable and valid alternative to clinician-ratings, especially when in person assessments are impractical or cost prohibitive for a particular study, or for observational or behavioral trials that are low risk. Our results indicated that self-reported ratings of functional capacity and functional ability internal consistency were good. Whereas clinician-reported ratings of the same constructs were excellent (and consistently higher than self-report ratings), the fact that the self-report ratings exceeded minimal acceptable criterion for internal consistency (i.e., > 0.70 [61] ) supports the reliability of the self-reported assessments. In addition, construct validity of self-reported functional ability and independence was supported by significant differences between those with premanifest, early-, and late-stage HD, such that those individuals with manifest HD (the early-and late-HD groups) reported less ability and independence than those with manifest HD, and those with late-stage HD reported less ability and independence than those with early-HD. This pattern of findings was identical for the associated clinician rating scores for both functional ability and independence. Although self-reported ratings significantly differed from clinician-ratings of the TFC (these differences were small, i.e., within 0.25 points of one another), and the agreement between individual items were not ideal, total scores agreed well on this measure. Self-report did not significantly differ from clinician-rated functional ability. When HD stage was considered, group differences were also not found between self-and clinician-reports for those with premanifest or latestage HD; there were group differences on self-and clinician-report for those with early-HD, but this difference was small (less than 1 point). Furthermore, whereas agreement at the item-level was poor, FA total scores showed good agreement. Self-report ratings significantly differed from clinician-ratings on the Independence Scale, but differences were small (within 0.5 of a point of one another). When HD stage was considered, self-and clinician-report differed for the two manifest groups but not the premanifest group; again differences were small (within 0.5 of a point for the early group and 0.75 of a point for the late-HD group). Furthermore, item-level agreement was not optimal, but total score agreement was acceptable. Thus, while these findings indicate that the self-report TFC, FA and Independence do not perfectly match the associated clinician-rated measures, the agreement is close enough to use with confidence in research studies that are behavioral or observational in design and are low risk, or where clinician-ratings are resource prohibitive or impractical.
Finally, Table 4 provides clinicians and researchers with recommendations for achieving specified levels of agreement. For example, if a clinician or researcher conducts a study utilizing self-reported TFC, they could be 75% confident that the self-reported score was within 2 points of the clinician-rated score, 90% confident that the clinician-rated score was within 4 points, 95% confident that it was within 5 points and 100% confident that it was within 7 points of clinician-rated TFC. On a scale where scores range from 0 to 13, one could rely solely on self-reported scores if 75% confidence was acceptable. If one wanted to achieve 90, 95, or 100% confidence, they would likely not rely on self-reported scores alone (as would likely be the case with medication based clinical trials). For FA, where scores range from 0 to 25, a clinician or researcher might be most comfortable using self-report if they required 90% agreement, in which case could be confident that the self-reported score was within 5 points of the clinician-rated score which is ± 20% of the score. Similarly, on Independence, where scores range from 0 to 100, a clinician or researcher might be most comfortable using self-report if they required 90-95% agreement (in which case we could be confident that the self-reported score was within 20 points of the clinician-rated score which is ± 20% of the score). Thus, while these discrepancies may preclude the use of these self-report measures in pharmacological trials (where measurement error can be especially problematic [62, 63] ), depending on the research question and the acceptable margin of error, Table 4 can be utilized to decide whether or not the benefits of using a self-reported score (efficiency, cost, etc.), exceeds the margin of error that would be acceptable for any given research questions.
This study provides support for self-reported functional capacity, ability and independence, and helps determine when one might consider only using self-report and not clinician-ratings of these scales. The study has some limitations. First, cognitive impairment is common in HD [27, 29, 64, 65 ], yet we did not administer any assessments to assess it directly, or estimate patient overall awareness in this study. Furthermore, we did not consider how other specific psychological or motivational factors such as depression, anxiety or apathy, may affect self-report or the relationship between self-report and clinician rating.
Regardless of these limitations, these findings provide important information for the clinical utility of the selfreported TFC, FA and Independence Scale. While the selfreported and clinician-rated scores are not identical, the selfreported versions demonstrated acceptable reliability. Any differences between scores were small, and there was generally good agreement for total scores supporting their clinical utility. Specifically, HD clinicians and researchers can consider administering the self-reported versions of these assessments when the study design permits, and obtaining clinician-ratings if not feasible (either because of cost or availability of clinician time). Funding Work on this manuscript was supported by the National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (R01NS077946) and the National Center for Advancing Translational Sciences (UL1TR000433). In addition, a portion of this study sample was collected in conjunction with the Predict-HD study. The Predict-HD was supported by the NIH, National Institute of Neurological Disorders and Stroke (R01NS040068), the NIH, Center for Inherited Disease Research (provided supported for sample phenotyping), and the CHDI Foundation (award to the University of Iowa).
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